Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flow from operating activities:
Net income	$ 1,277.2	$ 1,430.1
Adjustments to reconcile net income to net cash flow from operating activities:
Depreciation and amortization	277.9	219.8
Impairment of intangible assets	0.0	585.9
Excess and obsolescence charges related to inventory	305.6	8.3
Acquired in-process research and development	0.0	18.0
Share-based compensation	123.3	124.1
Contingent consideration	(11.6)	(33.5)
Deferred income taxes	(47.5)	(622.8)
(Gain) loss on strategic investments	269.3	283.6
(Gain) loss on equity method investments	(2.6)	(16.1)
Gain on sale of equity interest in Samsung Bioepis	(1,505.4)	0.0
Other	112.2	104.1
Changes in operating assets and liabilities, net:
Accounts receivable	(67.3)	211.5
Due from anti-CD20 therapeutic programs	(23.6)	(8.7)
Inventory	(243.3)	(193.8)
Accrued expense and other current liabilities	634.0	(188.4)
Income tax assets and liabilities	(65.9)	171.5
Other changes in operating assets and liabilities, net	(134.0)	(97.3)
Net cash flow provided by (used in) operating activities	898.3	1,996.3
Cash flows from investing activities:
Purchases of property, plant and equipment	(94.8)	(164.5)
Proceeds from sales and maturities of marketable securities	1,461.5	1,452.7
Purchases of marketable securities	(2,311.6)	(1,626.9)
Proceeds from sale of equity in Samsung Bioepis	(990.3)	0.0
Proceeds from divestiture of Hillerød, Denmark manufacturing operations	0.0	28.1
Acquisitions of intangible assets	(1.9)	0.0
Proceeds from the sales of strategic investments	0.0	91.2
Other	2.0	2.0
Net cash flow provided by (used in) investing activities	45.5	(217.4)
Cash flows from financing activities:
Purchases of treasury stock	(500.0)	(1,050.0)
Payments related to issuance of stock for share-based compensation arrangements, net	(11.5)	(14.2)
Repayment of borrowings and premiums paid on debt exchange	0.0	(170.0)
Net (distribution) contribution to noncontrolling interest	12.1	(94.8)
Other	11.4	(20.5)
Net cash flow provided by (used in) financing activities	(488.0)	(1,349.5)
Net increase (decrease) in cash and cash equivalents	455.8	429.4
Effect of exchange rate changes on cash and cash equivalents	(70.6)	(18.6)
Cash and cash equivalents, beginning of the period	2,261.4	1,331.2
Cash and cash equivalents, end of the period	$ 2,646.6	$ 1,742.0